From Amazon Agency
The research at Fcecon is supported by Fapeam
The effort to identify genetic mutations in suppressor and susceptibility genes associated with treatment resistance in patients with colorectal cancer (CRC) in the Amazon is a key goal of a state-sponsored study through the Amazonian Women and Girls program – public announcement. No 002/2021, Amazon State Research Support Foundation (Fapeam).
The Amazônidas program aims to promote the growth of the role of women in the local science, technology and innovation – CT&I scenario by providing research aid for capital expenditure, funding and scholarships to promote research projects as a positive measure.
The project involves a number of multidisciplinary researchers. It also aims to support the development of prevention strategies and quality of life assessment for patients with suspected or diagnosed colorectal adenocarcinoma treated by the Fundação Centro e Control de Oncologia do Estado do Amazonas (FCecon).
In addition, the research will broaden the scientific community’s understanding of the prognosis of the disease in relation to the factors being analyzed and shed light on new therapies for multimodal treatment of colorectal cancer, as emphasized by the research coordinator and the doctor of basic research. and Immunology Applied, FCecon, Valquiria do Carmo Alves Martins.
“This is a prospective longitudinal study whose qualitative approach characterizes clinical, epidemiological, immunological, cellular and molecular aspects and microbiota and evaluates the quality of life of patients with suspected or confirmed diagnosis of colon cancer. The researcher explains.”
The study began in February this year and has so far included 32 patients from FCecon, the reference institution for oncology in the Amazon and the north of the country, including 150 patients.
As a result, Valquiria Martins expects the consolidation of research, scientific and technological development and human resources at FCecon, both in terms of social and scientific impact, with the implementation of a new research line focusing on colorectal cancer.
Methods used in the study include sampling and removal of DNA from patients diagnosed with the disease, biopsy during surgery, or at FCecon. Following patient consent, biopsies and peripheral blood samples are collected and processed immediately and then stored.
The research also served as a basis for building a macro project “Analysis of the Molecular and Clinical Spectrum of Chorectal Cancer: From Epidemiology and Quality of Life to Genetics and Omics Analysis”.
According to the National Cancer Institute (Inca), colon cancer is currently the second type of tumor that kills most men and women, and it affects patients over the age of 45 or people with cases in the family. There is a sad sign in Brazil, 40 thousand new cases a year.
In the state of Amazonas, the incidence was 10 cases per 100,000 inhabitants, according to Inca 2020 data. The institute also estimates that there will be 230 new cases a year in the Amazon, 120 for men and 110 for women. In addition to the lack of more advanced symptoms and disease screening methods, the study has an impact on the current situation, especially in the state.
The Global Cancer Observatory, Globocan Brazil 2020, notes that, unlike other countries, CCR in Brazil is evenly distributed among both sexes, with more than 52,000 new cases and 25,000 deaths reported in the last year of 2020. Despite the fact that 80% of hospital admissions are related to the South and Southeast, incidence and mortality have doubled in the North and Northeast in recent years.